42 citations
,
May 2007 in “Endocrinology and metabolism/American journal of physiology: endocrinology and metabolism” Testosterone can build muscle and bone without enlarging the prostate when a specific enzyme is blocked.
2 citations
,
August 2016 in “British Journal of Clinical Pharmacology” The document concludes that women should not use 5-alpha-reductase inhibitors due to the risk of birth defects and limited effectiveness.
1 citations
,
November 2024 in “Expert Opinion on Drug Safety” Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.
5 citations
,
January 2018 in “Research Journal of Pharmacy and Technology” Finasteride significantly reduces fertility in male rats.
1 citations
,
November 2021 in “British Journal of Clinical Pharmacology” Saw palmetto may cause erectile dysfunction and needs better safety monitoring.
Finasteride, a medication, is being re-evaluated for its effects and uses.
4 citations
,
May 2018 in “BMC Musculoskeletal Disorders” Dutasteride and finasteride have similar risk for osteoporosis and fractures in older men.
Tamsulosin and finasteride together effectively slow down and prevent BPH progression.
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
49 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” The combination of cyproterone acetate and testosterone enanthate is highly effective in preventing sperm production and could be a good reversible male contraceptive.
April 2024 in “JCEM case reports” A man's breast enlargement from low-dose finasteride for hair loss didn't go away, even with treatment, and might be more common than reported.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
Finasteride may increase stroke risk in people with clotting tendencies.
1 citations
,
May 2024 in “The Journal of Sexual Medicine” Clomiphene Citrate can quickly restore fertility in some men after long-term steroid abuse.
September 2010 in “Institutional Repositories DataBase (IRDB)” Sorafenib can cause a temporary skin condition that goes away after stopping the drug.
Finasteride reduces prostate size and DHT in male mastomys but not in females.
39 citations
,
June 2019 in “Frontiers in Endocrinology” Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.
November 2005 in “PubMed” January 2024 in “Pharmaceutical journal/The pharmaceutical journal” Ritlecitinib can help about 14,000 people with severe hair loss.
January 2025 in “International Journal of Pharmaceutics” The treatment showed significant hair regrowth in alopecia areata patients without side effects.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
13 citations
,
June 2008 in “International Journal of Dermatology” Sorafenib can cause a unique skin reaction.
Three reliable methods were developed to measure Finasteride and Tamsulosin Hydrochloride in medicines.
A lotion with tretinoin, minoxidil, and betamethasone valerate helped treat a woman's skin infection.
111 citations
,
August 2002 in “Journal of Medicinal Chemistry” New compounds were made that block an enzyme linked to breast cancer better than existing treatments.
35 citations
,
May 2020 in “Frontiers in Pharmacology” Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
24 citations
,
January 1996 in “The Prostate” Finasteride is a safe and effective long-term treatment for prostate enlargement, reducing prostate volume and related symptoms.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
90 citations
,
December 2007 in “Current Oncology” Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.